- Home
- AMPL vs EWTX Comparison
AMPL vs EWTX Comparison
Compare AMPL & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMPL
- EWTX
- Stock Information
- Founded
- AMPL 2012
- EWTX 2017
- Country
- AMPL United States
- EWTX United States
- Employees
- AMPL N/A
- EWTX N/A
- Industry
- AMPL EDP Services
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- AMPL Technology
- EWTX Health Care
- Exchange
- AMPL Nasdaq
- EWTX Nasdaq
- Market Cap
- AMPL 1.7B
- EWTX 1.6B
- IPO Year
- AMPL 2021
- EWTX 2021
- Fundamental
- Price
- AMPL $10.03
- EWTX $14.95
- Analyst Decision
- AMPL Buy
- EWTX Buy
- Analyst Count
- AMPL 10
- EWTX 10
- Target Price
- AMPL $14.10
- EWTX $37.90
- AVG Volume (30 Days)
- AMPL 1.4M
- EWTX 957.0K
- Earning Date
- AMPL 11-05-2025
- EWTX 11-06-2025
- Dividend Yield
- AMPL N/A
- EWTX N/A
- EPS Growth
- AMPL N/A
- EWTX N/A
- EPS
- AMPL N/A
- EWTX N/A
- Revenue
- AMPL $316,571,000.00
- EWTX N/A
- Revenue This Year
- AMPL $15.04
- EWTX N/A
- Revenue Next Year
- AMPL $12.93
- EWTX N/A
- P/E Ratio
- AMPL N/A
- EWTX N/A
- Revenue Growth
- AMPL 9.93
- EWTX N/A
- 52 Week Low
- AMPL $7.55
- EWTX $10.60
- 52 Week High
- AMPL $14.88
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- AMPL 35.14
- EWTX 49.70
- Support Level
- AMPL $9.98
- EWTX $14.85
- Resistance Level
- AMPL $10.52
- EWTX $15.84
- Average True Range (ATR)
- AMPL 0.46
- EWTX 1.08
- MACD
- AMPL -0.16
- EWTX -0.06
- Stochastic Oscillator
- AMPL 5.21
- EWTX 31.42
About AMPL Amplitude Inc.
Amplitude Inc is a Software company that provides a Digital Analytics Platform that helps companies analyze their customer behavior within digital products. The Company delivers its application over the Internet as a subscription service using a software-as-a-service (SaaS) model and also it offers customer support related to initial implementation setup, ongoing support services, and application training. The company generates revenue primarily through selling subscriptions to the platform. The company derives a majority of its revenue from the United States.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.